- Home
- CMU vs AGEN Comparison
CMU vs AGEN Comparison
Compare CMU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMU
- AGEN
- Stock Information
- Founded
- CMU 1987
- AGEN 1994
- Country
- CMU United States
- AGEN United States
- Employees
- CMU N/A
- AGEN N/A
- Industry
- CMU Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMU Finance
- AGEN Health Care
- Exchange
- CMU Nasdaq
- AGEN Nasdaq
- Market Cap
- CMU 85.1M
- AGEN 87.7M
- IPO Year
- CMU N/A
- AGEN 2000
- Fundamental
- Price
- CMU $3.29
- AGEN $7.27
- Analyst Decision
- CMU
- AGEN Buy
- Analyst Count
- CMU 0
- AGEN 4
- Target Price
- CMU N/A
- AGEN $13.00
- AVG Volume (30 Days)
- CMU 82.4K
- AGEN 1.4M
- Earning Date
- CMU 01-01-0001
- AGEN 08-07-2025
- Dividend Yield
- CMU 4.08%
- AGEN N/A
- EPS Growth
- CMU N/A
- AGEN N/A
- EPS
- CMU 0.07
- AGEN N/A
- Revenue
- CMU N/A
- AGEN $99,524,000.00
- Revenue This Year
- CMU N/A
- AGEN $12.69
- Revenue Next Year
- CMU N/A
- AGEN N/A
- P/E Ratio
- CMU $47.57
- AGEN N/A
- Revenue Growth
- CMU N/A
- AGEN N/A
- 52 Week Low
- CMU $2.78
- AGEN $1.38
- 52 Week High
- CMU $3.38
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- CMU 37.74
- AGEN 68.42
- Support Level
- CMU $3.34
- AGEN $4.78
- Resistance Level
- CMU $3.34
- AGEN $6.20
- Average True Range (ATR)
- CMU 0.03
- AGEN 0.62
- MACD
- CMU -0.00
- AGEN 0.10
- Stochastic Oscillator
- CMU 0.00
- AGEN 98.90
About CMU MFS Municipal Income Trust
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).